Page 21 - Gene Therapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AIDS@40: Stories of hope and heroes The people and the science devoted to stopping HIV Álex Cámara / Getty Images June 5, 2021, will mark 40 years since Los Angeles physician Dr. Michael Gottlieb and colleagues published the first medical account of what would eventually become known as AIDS. It was a short summary in the Centers for Disease Control and Prevention’s printed weekly newsletter of five cases of pneumonia in gay men, all of whom eventually died. The global story that has unfolded since is an unspeakable tragedy. HIV/AIDS has claimed more than 32.7 million lives, d...

Date Time Discovery Labs Signs Foundational Lease with University of Pennsylvania Gene Therapy Program as Anchor Tenant KING OF PRUSSIA, Pa., (May , 2021) – The Discovery Labs has signed a foundational lease with the University of Pennsylvania Gene Therapy Program (GTP), which will use Discovery Labs’ suburban campus for a portion of its expanding research operations focused on the development of genetic medicines for rare and orphan diseases, as well as acquired and pandemic infectious diseases, such as COVID-19. The lease with Penn’s Gene Therapy Program—led by James M. Wilson, MD,...

/PRNewswire/ -- The Discovery Labs has signed a foundational lease with the University of Pennsylvania Gene Therapy Program (GTP), which will use Discovery...

Published: May 19, 2021   Joined an alliance of life science companies dedicated to rare disease therapy development to support advocacy for policies that will improve processes for timely and cost-effective delivery of treatments   DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has joined the newly form...

Published: May 13, 2021   Mary Newman, former SVP of Regulatory Affairs at Astellas Gene Therapies, joins Taysha with over 30 years of experience in regulatory affairs and research and development in the biotech industry Extensive experience deeply rooted in gene therapy at Astellas Gene Therapies, Audentes Therapeutics and BioMarin   DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous sy...